Advertisement

PRXL

PAREXEL Intl Corp.

Healthcare

Set alert

Price alert · PRXL

All alert types
88.08 0.00 0.00%
As of Jun 28, 2019
88.07 Day range 88.10
51.16 52-week range 88.10
Open
88.10
Prev close
88.08
Mkt cap
4.50B
Vol
7.02M
Avg vol
828.03K
EPS
2.06
P/E
42.76
Div yield
0.00%
More statistics
Low
88.07
High
88.10
Forward P/E
19.70
Beta
0.70
Short ratio
0.57
Inst. own
90.14%
Dividend
0.00
Ex-div date
50-d avg
88.02
200-d avg
82.58
1y target
88.70

2Y chart

Chart tools
Interval

Chart is warming up

The two-year price history for PRXL has not been loaded yet. Try again in a moment.

Key statistics

Market cap
4.50B
Enterprise value
4.87B
Trailing P/E
42.76
Forward P/E
19.70
PEG ratio
0.00
Price / sales
2.13
Price / book
7.09
EPS (TTM)
2.06
Beta
0.70
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
5.07%
Revenue (TTM)
2.12B
Revenue growth
3.80%
Free cash flow
247.82M
Total cash
302.70M
Total debt
671.50M
Return on equity
16.93%
Shares outstanding
51.12M
Short % of float
0.97%
50-day average
88.02
200-day average
82.58

Analyst view

Consensus: hold

Hold
Price target (mean) 88.70 +0.7% upside
Target (low)
88.00
Target (mean)
88.70
Target (high)
90.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
PRXL Revenue — quarterly 647.60M
2014-Q1 20132014-Q2 20132014-Q3 20142014-Q4 20142015-Q1 20142015-Q2 20142015-Q3 20152015-Q4 20152016-Q1 20152016-Q2 20152016-Q3 20162016-Q4 20162017-Q1 20162017-Q2 20162017-Q3 20172017-Q4 2017
PRXL Net income — quarterly 29.90M
2014-Q1 20132014-Q2 20132014-Q3 20142014-Q4 20142015-Q1 20142015-Q2 20142015-Q3 20152015-Q4 20152016-Q1 20152016-Q2 20152016-Q3 20162016-Q4 20162017-Q1 20162017-Q2 20162017-Q3 20172017-Q4 2017
PRXL EPS — quarterly 0.59
2014-Q1 20132014-Q2 20132014-Q3 20142014-Q4 20142015-Q1 20142015-Q2 20142015-Q3 20152015-Q4 20152016-Q1 20152016-Q2 20152016-Q3 20162016-Q4 20162017-Q1 20162017-Q2 20162017-Q3 20172017-Q4 2017

Earnings

PRXL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
May 8, 2017Mar 31, 2017—0.34——
Feb 8, 2017Dec 31, 2016—0.42——
Nov 14, 2016Sep 30, 2016—0.71——
Sep 29, 2016Jun 30, 2017—0.58——
Feb 2, 2016Dec 31, 2015—0.73——
Sep 29, 2015Jun 30, 2016—0.80——

Upgrades / downgrades

PRXL analyst upgrades and downgrades
DateFirmActionFromTo
May 22, 2017Goldman Sachsup—Neutral
May 14, 2017Evercore ISI Groupup—Outperform
Feb 5, 2017Credit Suissedown—Neutral
Feb 2, 2017Citigroupdown—Neutral
Feb 2, 2017Deutsche Bankdown—Sell
Jan 3, 2017Evercore ISI Groupdown—Hold

About PAREXEL Intl Corp.

PAREXEL International Corporation, a biopharmaceutical outsourcing services company, provides clinical research and logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting Services (PC), and PAREXEL Informatics (PI). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management, and biostatistical analysis, epidemiology and health economics/outcomes research, clinical supply and drug logistics, pharmacovigilance, commercialization, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. The PC segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, commercialization, and strategic compliance; and market and product development, and targeted communications services to support product launch, as well as offers solutions to address client issues associated with product development, registration, and commercialization. The PI segment provides information technology solutions comprising ClinPhone randomization and trial supply management solutions, medical imaging services, IMPACT clinical trial management systems, LIQUENT InSight regulatory information management software and professional services, DataLabs electronic data capture systems, Web-based portals, systems integration services, electronic patient reported outcomes, and patient diary applications, as well as centralized assessment services for patient technology solutions. PAREXEL International Corporation was founded in 1983 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Medical Laboratories & Research
Country
United States
Website
parexel.com

News

Your note

Sign in to keep a note on PRXL — it syncs with the Stock Master app.

Insider holders

PRXL insider holders
InsiderRelationLatest transactionDateShares held
ANDERSSON ROLANDOfficerDisposition (Non Open Market)Sep 28, 20170
BANK INGOOfficerDisposition (Non Open Market)Jul 7, 201621,245
BATT DOUGLAS AOfficerDisposition (Non Open Market)Sep 28, 20170
CALLOW A DANA JRDirectorDisposition (Non Open Market)Sep 28, 20170
FLINOIS XAVIEROfficerDisposition (Non Open Market)Sep 28, 20170
FORTUNE PATRICK JDirectorDisposition (Non Open Market)Sep 28, 20170

Institution ownership

PRXL institution ownership
Holder% heldSharesValueReported
Blackrock Inc.10.63%5,432,566472.69MJun 29, 2017
Vanguard Group, Inc. (The)8.23%4,205,566365.93MJun 29, 2017
Fisher Asset Management, LLC4.14%2,114,547183.99MJun 29, 2017
State Street Corporation3.41%1,744,373151.78MJun 29, 2017
Alpine Associates Management Inc.2.56%1,308,435113.85MJun 29, 2017
CNH Partners LLC2.47%1,265,075110.07MJun 29, 2017

Fund ownership

PRXL fund ownership
Holder% heldSharesValueReported
iShares Core S&P Midcap ETF2.38%1,215,080105.72MJun 29, 2017
Vanguard Small-Cap Index Fund2.33%1,190,58574.65MMar 30, 2017
Vanguard Total Stock Market Index Fund2.22%1,132,59671.01MMar 30, 2017
Vanguard Specialized-Health Care Fund2.17%1,108,78570.26MApr 29, 2017
iShares Russell 2000 ETF1.91%974,28884.77MJun 29, 2017
Vanguard Small-Cap Growth Index Fund1.27%651,30140.84MMar 30, 2017
Advertisement